US Neonatal Mortality Rate: Unveiling the Perinatal Causes
TOPLINE:
The neonatal mortality rate in the US decreased from 1999 to 2022, with deaths from interstitial emphysema and related conditions showing the steepest decline, yet mortality from slow fetal growth and malnutrition rose by nearly 2% annually.
METHODOLOGY:
A retrospective study was conducted to examine neonatal mortality rates from 1999 to 2022 using data sourced from CDC Wide-Ranging Online Data for Epidemiologic Research, with diagnostic codes used to identify the cause of death related to perinatal complications.
The top 10 causes of neonatal death were identified based on cumulative frequency over the study period.
Mortality rates were stratified by sex, delivery method, birthplace, and age at death.
TAKEAWAY:
From 1999 to 2022, 283,696 neonatal deaths were reported owing to perinatal complications, with male neonates accounting for 56.2% of deaths. The top 10 causes accounted for 79.8% of the deaths.
Disorders related to short gestation and low birth weight were the leading cause of neonatal deaths, with a crude rate of 102.10 per 100,000 live births. They were followed by deaths in newborns due to maternal complications of pregnancy and issues related to the placenta, cord, and membranes.
Mortality from interstitial emphysema and related conditions showed a steep decline, followed by respiratory distress from the perinatal period, with annual average percent changes of -5.40% (95% CI, -6.20% to -4.64%) and -3.63% (95% CI, -4.45 to -3.00), respectively.
Mortality from slow fetal growth and fetal malnutrition increased by 1.91% annually (95% CI, 0.46%-3.82%), whereas mortality due to maternal complications and bacterial sepsis in newborns remained stable.
IN PRACTICE:
'US neonatal mortality has generally decreased, likely due to medical advancements, improved prenatal care, and neonatal intensive care interventions.' the authors wrote. 'Vaginal deliveries were associated with nearly three times the neonatal mortality rate of cesarean deliveries, potentially due to complications, such as birth trauma and prolonged labor.'
SOURCE:
This study was led by Muzamil Khan, MD, of the George Washington University School of Medicine and Health Sciences in Washington, DC. It was published online on June 23, 2025, in JAMA Pediatrics.
LIMITATIONS:
This study could not assess important nutritional factors, such as exclusive breastfeeding rates, which may influence malnutrition outcomes. It focused only on perinatal causes influenced by healthcare and excluded congenital malformations. Each death was assigned a single diagnostic code, limiting the capture of coexisting conditions.
DISCLOSURES:
No funding source or conflicts of interest were disclosed by the authors.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
12 minutes ago
- CNN
New CDC vaccine advisers vote to recommend Merck RSV antibody protection for babies
Vaccines Federal agencies Respiratory viruses Prescription drugsFacebookTweetLink Follow A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend the use of a new shot that can protect babies from respiratory syncytial virus, adding an additional tool against the most common cause of hospitalization in infants. The vote was the first for the newly assembled group, which was appointed by US Health and Human Services Secretary Robert F. Kennedy Jr. earlier this month after he dismissed the previous panel of 17 experts, claiming they had conflicts of interest. The split revealed tensions around the committee, some members of which have raised serious concerns from the public health community for their approach to vaccines and scientific evidence. The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a common virus that can be especially dangerous for infants. One, like clesrovimab, is an antibody shot, while another is a vaccine given during pregnancy. Data presented at the meeting showed the approved interventions were safe and dramatically reduced hospitalizations among babies from RSV in the last respiratory virus season. 'As a pediatrician, I mean, people need to understand what a spectacular accomplishment these results are,' ACIP member Dr. Cody Meissner, a professor of pediatrics at Dartmouth Geisel School of Medicine, said on Wednesday. They 'will have an enormous influence on public health.' The new drug was approved earlier this month by the US Food and Drug Administration, and the CDC committee's recommendation was the next step in making it widely available for the coming RSV season, which typically begins in the fall. The recommendation now goes to the CDC director or potentially to Kennedy, as CDC nominee Dr. Susan Monarez is still awaiting Senate confirmation. The vote came after Dr. Retsef Levi, a professor of operations management at the Massachusetts Institute of Technology Sloan School of Management and one of the new panelists, raised questions Thursday morning about whether there were safety signals that arose in clinical trials of the antibody shots that deserve further scrutiny. Representatives from both the FDA and Merck emphasized the safety of the product and the rigor of the clinical trials. Meissner also expressed how thoroughly the CDC panel's work group on RSV examined the data. 'We went through the details very, very carefully, and I appreciate Dr. [Levi's] careful review of the records, but the workgroup is comfortable with the results from the different clesrovimab trials,' he said. Levi voted against recommending the Merck shot, joined by Dr. Vicky Pebsworth, volunteer director of research and patient safety at the National Vaccine Information Center, a group that emphasizes risks around vaccines while downplaying their benefit. The vote was closely watched as a first signal of how the controversial new committee would approach immunization policy. The Advisory Committee on Immunization Practices, or ACIP, is tremendously influential in how vaccines are used in the US, with implications for insurance coverage and state policies. Kennedy's upheaval of the group led organizations like the American Academy of Pediatrics this week to break with the ACIP over concerns about scientific integrity. In a second vote on the Merck shot Thursday, the group voted unanimously that it should be included in the Vaccines for Children Program, which provides free vaccines to children whose families may not be able to afford them.
CNN
18 minutes ago
- CNN
New CDC vaccine advisers vote to recommend Merck RSV antibody protection for babies
Vaccines Federal agencies Respiratory viruses Prescription drugsFacebookTweetLink Follow A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend the use of a new shot that can protect babies from respiratory syncytial virus, adding an additional tool against the most common cause of hospitalization in infants. The vote was the first for the newly assembled group, which was appointed by US Health and Human Services Secretary Robert F. Kennedy Jr. earlier this month after he dismissed the previous panel of 17 experts, claiming they had conflicts of interest. The split revealed tensions around the committee, some members of which have raised serious concerns from the public health community for their approach to vaccines and scientific evidence. The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a common virus that can be especially dangerous for infants. One, like clesrovimab, is an antibody shot, while another is a vaccine given during pregnancy. Data presented at the meeting showed the approved interventions were safe and dramatically reduced hospitalizations among babies from RSV in the last respiratory virus season. 'As a pediatrician, I mean, people need to understand what a spectacular accomplishment these results are,' ACIP member Dr. Cody Meissner, a professor of pediatrics at Dartmouth Geisel School of Medicine, said on Wednesday. They 'will have an enormous influence on public health.' The new drug was approved earlier this month by the US Food and Drug Administration, and the CDC committee's recommendation was the next step in making it widely available for the coming RSV season, which typically begins in the fall. The recommendation now goes to the CDC director or potentially to Kennedy, as CDC nominee Dr. Susan Monarez is still awaiting Senate confirmation. The vote came after Dr. Retsef Levi, a professor of operations management at the Massachusetts Institute of Technology Sloan School of Management and one of the new panelists, raised questions Thursday morning about whether there were safety signals that arose in clinical trials of the antibody shots that deserve further scrutiny. Representatives from both the FDA and Merck emphasized the safety of the product and the rigor of the clinical trials. Meissner also expressed how thoroughly the CDC panel's work group on RSV examined the data. 'We went through the details very, very carefully, and I appreciate Dr. [Levi's] careful review of the records, but the workgroup is comfortable with the results from the different clesrovimab trials,' he said. Levi voted against recommending the Merck shot, joined by Dr. Vicky Pebsworth, volunteer director of research and patient safety at the National Vaccine Information Center, a group that emphasizes risks around vaccines while downplaying their benefit. The vote was closely watched as a first signal of how the controversial new committee would approach immunization policy. The Advisory Committee on Immunization Practices, or ACIP, is tremendously influential in how vaccines are used in the US, with implications for insurance coverage and state policies. Kennedy's upheaval of the group led organizations like the American Academy of Pediatrics this week to break with the ACIP over concerns about scientific integrity. In a second vote on the Merck shot Thursday, the group voted unanimously that it should be included in the Vaccines for Children Program, which provides free vaccines to children whose families may not be able to afford them.
CBS News
an hour ago
- CBS News
Mosquitos in Northern Colorado county test positive for West Nile virus
This week, a sample of the mosquito population in Larimer County in Northern Colorado tested positive for West Nile virus. County health officials say this marks the beginning of heightened risk for residents, as warmer weather and rain lead to more mosquito activity. About 1 in 5 people infected may develop flu-like symptoms, including fever, headaches, body aches, fatigue, vomiting, diarrhea, and rash. About 1 in 150 people who are infected develop more severe illness, which includes symptoms of high fever, headache, tremors, muscle weakness, vision loss and paralysis. Mosquitos in Larimer County have tested positive for West Nile Virus. CBS When Lisa Montez visited Fort Collins in the summer of 2022, she never imagined a mosquito bite would turn her life upside down. What started as mild fatigue turned into a months-long ordeal that left her unable to drive, plagued by chronic fatigue, and permanently impacted by the bite. "The next day, I woke up and was very, very tired. But I figured, because I was traveling and we were with family, that it was just a normal vacation tied," Montez said. She returned home to Washington. Within days, Montez broke out in a full-body rash. Doctors initially suspected something minor - maybe an ear infection or just a viral bug. But despite multiple visits to urgent care and emergency rooms, her condition worsened with no clear answers. It took two months and a battery of tests before doctors finally diagnosed her with West Nile virus. Montez, a healthy woman in her 30s, ended up with a rare neuroinvasive form of the illness. CBS Colorado's Tori Mason walks with Lisa Montez. CBS "My husband was doing everything on his own. I couldn't do laundry, I couldn't cook, I couldn't clean. A lot of times I was just in bed because I was so dizzy or I was so tired," she explained. She wasn't able to drive a car for about a year. Her family returned to Colorado to get support from family and treatment at UCHealth. Montez was in vestibular rehab for 11 months and in occupational therapy for eight months. "I think that had we not come back, I wouldn't be where I am, and I wouldn't have progressed as far as I have through this with the support that I had. So I'm very grateful for UCHealth and for all of the time that they invested," she said. People ages 55 and older are at higher risk of serious symptoms if they get West Nile virus. People with health conditions such as cancer, diabetes, and hypertension, and who have had organ transplants or are taking medications that suppress the immune system, are also at risk. There are no vaccines to prevent West Nile virus. Dr. Bob Belknap, Director of the Public Health Institute at Denver Health, says if people have it, it's supportive care. "If someone is feeling sick, and if they have any concern at all, we recommend that they seek medical care. Do not hesitate. People usually know if something is mild and it's manageable, something they can treat with over-the-counter medications," he said. "If it's at all concerning, or if it's getting worse despite those treatments, then definitely people should seek care." Larimer County CBS The Health Department urges all residents to adopt effective protective measures as part of their summer routine: Regularly use an EPA-registered insect repellent. Wear loose-fitting long-sleeved shirts and pants for long walks, gardening, and other times outside. Avoid outdoor activities during peak biting times around dawn and dusk. Montez says the experience completely reshaped how she approaches outdoor activities. She hopes her experience reminds others not to brush off those bites. "I have nerve damage in my body. My left side was impacted more than the rest of my body, so I have weakness in the left side of my body. I actually have a little bit of drooping in this side of the face," she said. "I'm better today, but I will have lifelong effects from this."
